A Phase 2, Multicenter Study of Cabazitaxel Single Agent Administered as a 1-Hour Intravenous Infusion Every 3 Weeks to Evaluate the Safety, Tolerability and Anti-tumor Activity of Cabazitaxel in Patients With Advanced Gastric Adenocarcinoma Who Have Failed Prior Chemotherapy Regimens.

Trial Profile

A Phase 2, Multicenter Study of Cabazitaxel Single Agent Administered as a 1-Hour Intravenous Infusion Every 3 Weeks to Evaluate the Safety, Tolerability and Anti-tumor Activity of Cabazitaxel in Patients With Advanced Gastric Adenocarcinoma Who Have Failed Prior Chemotherapy Regimens.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2015

At a glance

  • Drugs Cabazitaxel (Primary)
  • Indications Gastric cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms GASTANA
  • Sponsors Sanofi
  • Most Recent Events

    • 18 Jan 2014 Interim results presented at the 2014 Gastrointestinal Cancers Symposium.
    • 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Jan 2012 Planned End Date changed from 1 Sep 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top